January 2nd 2024
To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.
December 26th 2023
Drs Saeed and Singal discuss additional data presented at AASLD 2023 related to frontline systemic therapies and emerging combinations in unresectable HCC.
Expert oncologists review real-world data and discuss the impact on treatment selection in uHCC.
December 19th 2023
An expert analysis in data surrounding treatment outcomes in combination regimens, noting immune-mediate adverse events and overall impact on treatment response.
Dr. Saeed outlines the use of combination tremelimumab plus durvalumab in uHCC, discussing updates from the HIMALAYA trial presented at AASLD 2023.
December 12th 2023
A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.
Anwaar Saeed, MD, and Amit Singal, MD, discuss the evolving treatment landscape for hepatocellular carcinoma, highlighting FDA approvals and the utility of clinical biomarkers.
March 2nd 2023
Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.